Who are Rapid-tapering glucocorticoids + Inebilizumab's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Slow-tapering glucocorticoids + Inebilizumab.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/rapid-tapering-glucocorticoids-inebilizumab.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

Rapid-tapering glucocorticoids + Inebilizumab — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Rapid-tapering glucocorticoids + Inebilizumab (Rapid-tapering glucocorticoids + Inebilizumab) competitive landscape: 1 comparator, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Monoclonal antibody + Glucocorticoid combination. Area: Immunology / Autoimmune disease.

phase 3 Monoclonal antibody + Glucocorticoid combination BDCA-2 (on pDCs) + Glucocorticoid receptor Immunology / Autoimmune disease Small molecule Live · refreshed every 30 min

Target snapshot

Rapid-tapering glucocorticoids + Inebilizumab (Rapid-tapering glucocorticoids + Inebilizumab) — Tianjin Medical University General Hospital. Inebilizumab, a monoclonal antibody targeting plasmacytoid dendritic cells (pDCs), reduces pathogenic B cell and autoantibody production, combined with rapid-tapering glucocorticoids to suppress acute inflammation in autoimmune disease.

Comparator set (1 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Rapid-tapering glucocorticoids + Inebilizumab TARGET	Rapid-tapering glucocorticoids + Inebilizumab	Tianjin Medical University General Hospital	phase 3	Monoclonal antibody + Glucocorticoid combination	BDCA-2 (on pDCs) + Glucocorticoid receptor
Slow-tapering glucocorticoids + Inebilizumab	Slow-tapering glucocorticoids + Inebilizumab	Tianjin Medical University General Hospital	phase 3	Monoclonal antibody + Glucocorticoid combination	BDCA-2 (CD320) on plasmacytoid dendritic cells; glucocorticoid receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Monoclonal antibody + Glucocorticoid combination class)

Tianjin Medical University General Hospital · 2 drugs in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Rapid-tapering glucocorticoids + Inebilizumab — Competitive Intelligence Brief. https://druglandscape.com/ci/rapid-tapering-glucocorticoids-inebilizumab. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab